Picture of Biopharma Credit logo

BPCP Biopharma Credit News Story

0.000.00%
gb flag iconLast trade - 00:00
FinancialsConservativeMid CapSuper Stock

REG - BioPharma Credit PLC - Notice of AGM

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260506:nRSF0959Da&default-theme=true

RNS Number : 0959D  BioPharma Credit PLC  06 May 2026

6 May 2026

BioPharma Credit plc

(the "Company")

NOTICE OF ANNUAL GENERAL MEETING

 

Following the publication of the Company's Annual Financial Report for the
year ended 31 December 2025 on 24 March 2026, the Company announces that it
will hold its 2026 Annual General Meeting ("AGM") at 1.00 p.m. on 17 June 2026
at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose
Street, London EC2A 2EG.

 

A copy of the Notice of the AGM is available to view on the Company's website
at https://bpcruk.com/investor-materials/
(https://bpcruk.com/investor-materials/) . It has also been submitted to the
National Storage Mechanism and is available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . Copies of the
Notice of the AGM have been posted or made available to the Company's
Shareholders.

 

 

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Henry Wilson / Helen Tarbet  /Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

 

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASSSFEIEMSEDI



            Copyright 2019 Regulatory News Service, all rights reserved

Recent news on Biopharma Credit

See all news